4SC
VC Fund
Planegg, Germany
4SC is a VC fund in Planegg focused on Health Care and Biotechnology. 4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries 4SC invests in
Stages 4SC invests in
Countries 4SC invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Frank Hermann
Chief Development Officer
|
Chief Development Officer | Total investments: 0 | Find email | |
Jason Loveridge
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Susanne Danhauser-Riedl
Chief Medical Officer
|
Chief Medical Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Panoptes Pharma
|
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria.The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease whichis one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications.Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development. | Seed / Nov 02, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does 4SC invest in?
4SC invests primarily in Health Care and Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact 4SC?
Public channels for 4SC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 4SC?
The team at 4SC includes Frank Hermann (Chief Development Officer), Jason Loveridge (Chief Executive Officer) and Susanne Danhauser-Riedl (Chief Medical Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
